Vasogen Completes Registered Direct Offering of Common Shares

Vasogen, focused on the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease, has completed its previously announced registered direct offering of approximately 9 million of its common shares at a price of US$4.70 per share to institutional investors, for gross proceeds of approximately $42.3 million. The shares were offered under the company's existing shelf registration statement, as amended, and this offering completes the balance of this shelf registration.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-02-2005/0002945236&EDATE=)